Patients with psoriasis face increased ESRD risk, but systemic treatment may help

  • Lee E & al.
  • Sci Rep
  • 12.11.2019

  • von Brian Richardson, PhD
  • Clinical Essentials
Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten. Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten.

Takeaway

  • Patients with psoriasis are at increased risk of end-stage renal disease (ESRD), although this association is not found in patients who received systemic treatment, according to a population study.

Why this matters

  • The risk of ESRD in patients with psoriasis was unclear.

Key results

  • Psoriasis was associated with increased risk of ESRD in adjusted analysis (HR, 1.58; P<.001>
  • Psoriatic arthritis was associated with a further increased risk of ESRD in adjusted analysis (HR, 7.60; P<.001>
  • In subgroup, psoriasis was significantly associated with ESRD risk in patients who did not receive systemic treatment (HR, 1.60; P<.001 but not in patients who received systemic treatment ci>
  • Patients treated with acitretin (Soriatane) had a reduced risk of ESRD (HR, 0.576; 95% CI, 0.385-0.863) compared with patients who did not receive systemic treatment.

Study design

  • 2,121,228 adult subjects, 530,307 with psoriasis, were analyzed for ESRD risk.
  • Funding: National Research Foundation of the Republic of Korea.

Limitations

  • Observational study of large database.